936727-34-3

Usage

Uses

Used in Pharmaceutical Industry:
(4-CHLORO-3-HYDROXYPHENYL)ACETONITRILE is used as an intermediate for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key building block in the development of new drugs, contributing to the advancement of medical treatments and therapies.
Used in Agrochemical Industry:
In the agrochemical industry, (4-CHLORO-3-HYDROXYPHENYL)ACETONITRILE is utilized as an intermediate in the production of various agrochemicals. Its application in this field aids in the development of chemicals that can enhance crop protection and improve agricultural productivity.
Used in Chemical Synthesis:
(4-CHLORO-3-HYDROXYPHENYL)ACETONITRILE serves as a crucial building block in the synthesis of a wide range of chemicals. Its versatility and reactivity make it a valuable component in the creation of diverse chemical compounds for various applications across different industries.

Upstream product

• 13726-21-1 2-(4-chloro-3-methoxyphenyl)acetonitrile 
• 73909-16-7 2-chloro-5-methylanisole 
• 103347-14-4 4-(bromomethyl)-1-chloro-2-methoxybenzene 
• 615-74-7 2-chloro-5-methylphenol 

Downstream Products

• 936727-47-8 2-(3-(benzyloxy)-4-chlorophenyl)acetonitrile 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.